Author: Nigel SB Rawson (Ph.D.)
Health technology assessment has been called the fourth ‘hurdle’ in the process of getting drugs to patients. This study investigates the impact of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations and Common Drug Review (CDR) recommendations on provincial benefit listings to assess whether the pCPA has become another hurdle to new drug access for Canadian patients.
